This bill addresses restrictions on drug manufacturers’ interactions with 340B covered entities, which are healthcare organizations that qualify for discounted drug pricing under a federal program. Specifically, the bill prohibits manufacturers from directly or indirectly interfering with a pharmacy’s ability to acquire, deliver, or dispense 340B drugs (medications purchased at reduced prices) on behalf of covered entities. The bill also prevents manufacturers from requiring covered entities to submit claims or utilization review data as a condition for acquiring, delivering, or dispensing these drugs, unless such requirements are mandated by the U.S. Department of Health and Human Services. For violations of these provisions, the State Board of Pharmacy can impose a civil penalty of up to $5,000 per day. The bill defines key terms such as “covered entity” (based on federal law), “manufacturer” (based on Oregon state law), and “340B drug” to provide clarity and ensure precise implementation of the restrictions.